MLYS - Mineralys Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

330.2M

Cash

338.6M

Avg Qtr Burn

-21.88M

Short % of Float

6.71%

Insider Ownership

2.53%

Institutional Own.

96.14%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Lorundrostat Details Chronic kidney disease, Hypertension	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lorundrostat Details Hypertension	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.